Loading clinical trials...

Combating Alzheimer's Through Sleep and Exercise | Clinical Trials | Clareo Health

RECRUITINGNA

Combating Alzheimer's Through Sleep and Exercise

Combating Alzheimer's Through Sleep and Exercise (CASE)

NCT04855630•University of Miami

View on ClinicalTrials.gov

Summary

The purpose of this research is to see how sleep and exercise affects dementia risk over time.

Eligibility

Age

45 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Able to perform mild exercise
•2. Able to wear DREEM 2 Headband
•3. Able to wear a Fitbit wrist watch
•4. Able to perform the Everlywell biomarker procedure
•5. Able to Understand and Speak English
•6. Able to operate a digital device like mobile phone, iPad, or computer
•7. Self-reported history of problems with cognitive impairment: memory, concentration, and processing information
•8. Only participants cognitively able and willing to provide consent will be included.

Exclusion Criteria

•1. Prohibited from or unable to perform mild exercise
•2. Unable to wear wrist watch or headband devices, or unable to supply pinprick blood sample for any reason
•3. Unable to speak or understand English
•4. Unable to use mobile device/smartphone technology
•5. Unable or unwilling to consent for any reason.

Locations (1)

University of Miami Hospitals

Miami, Florida, United States

Key Dates

Start Date

March 1, 2023

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

February 24, 2025

Enrollment

ESTIMATED participants

Conditions

Alzheimer DiseaseDementia

Interventions

DREEM 2 Headband

DEVICE

Exercise Routine

OTHER

Contacts

Azizi A Seixas, PhD

CONTACT

3052431301 Azizi.seixas@med.miami.edu

Debbie Chung, PhD

CONTACT

3052431301 dxc1729@miami.edu

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Combating Alzheimer's Through Sleep and Exercise

Inclusion Criteria

Exclusion Criteria

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Testing the Pain Clinical Practice Guideline